ASCO 2023：最全汇总！乳腺癌Oral Abstract Session速览！

一年一度的全球肿瘤学盛会——第59届2023年美国临床肿瘤学会（ASCO 2023）年会定于美国芝加哥当地时间2023年6月2日~6日正式拉开帷幕，包括 200 个口头报告研究（Oral abstract）、2000 ＋壁报展示（Poster session）、46 场临床科学研讨会（Clinical Science Symposium）等！

乳腺癌癌领域也将迎来多项重磅研究进展。梅斯医学将于会议前后持续更新相关内容，一起来看吧！

Oral Abstract Session

摘要号LBA1000

题目：Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the

optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with

hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

报告人：Gabe S. Sonke

摘要号1001

题目：Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in pa-

tients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor re-

ceptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

报告人：Antonio Llombart-Cussac

摘要号1002

题目：Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined

with palbociclib after randomization in the PADA-1 trial.

报告人：Luc Cabel

摘要号1003

题目：Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab

govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/

HER2–) metastatic breast cancer (mBC).

报告人：Sara M. Tolaney

摘要号1004

题目：A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).

报告人：Erika P. Hamilton

摘要号1005

题目：Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The

impact of repeat biopsies.

报告人：Yael Bar

摘要号1006

题目：An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with

HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and

-03.

报告人：Ian E. Krop

摘要号1007

题目：Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in

metastatic breast cancer: The X-7/7 trial.

报告人：Qamar J. Khan

摘要号1008

题目：CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer

receiving palbociclib and endocrine therapy and the affect on time to deterioration of

quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.

报告人：Nadia Harbeck

摘要号LBA500

题目：Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients

with HR+/HER22 early breast cancer.

报告人：Dennis J. Slamon

摘要号501

题目：Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with

endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast

cancer (EBC).

报告人：Erika P. Hamilton

摘要号502

题目：Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to

anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the

PENELOPE-B trial.

报告人：Nicholas C. Turne

摘要号503

题目：Effects of ovarian ablation or suppression on breast cancer recurrence and survival:

Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.

报告人：Richard G. Gray

摘要号504 Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in pre-

题目：menopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT

Trial.

报告人：Lauren Claire Brown

摘要号505

题目：Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics

and prognosis in young women with HR+/HER2- breast cancer (BC).

报告人：Megan E Tesch

摘要号LBA506

题目：3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II

PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth

factor receptor 2-positive (HER2[+]) early breast cancer (EBC).

报告人：Javier Cortes

摘要号507

题目：Differential impact of proliferation signature on efficacy of neoadjuvant chemo-

immunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker

analysis of the NeoPACT trial.

报告人：JShane R Stecklein

摘要号508

题目：Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for

HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women

in 5 trials.

报告人：Robert Kerrin Hills